C3 Jian raises $30m to fund Phase I trials for tooth decay drug
This article was originally published in Scrip
Executive Summary
In an incisive, oral health drug developer C3 Jian Inc. garnered $30 million in its third round of equity financing to fund human clinical trials for its lead candidate C16G2, a peptide drug targeting tooth decay.